Search: L773:0149 5992 OR L773:1935 5548 >
Inhibition of dipep...
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.
-
- Ahrén, Bo (author)
- Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Simonsson, Erik (author)
-
Larsson, Hillevi (author)
-
show more...
-
- Landin-Olsson, Mona (author)
- Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Torgeirsson, Hlin (author)
-
Jansson, Per-Anders (author)
-
Sandqvist, Madeléne (author)
-
Båvenholm, Peter (author)
-
Efendic, Suad (author)
-
- Eriksson, Jan W (author)
- Uppsala universitet,Endokrin diabetes och metabolism
-
Dickinson, Sheila (author)
-
Holmes, David (author)
-
show less...
-
(creator_code:org_t)
- American Diabetes Association, 2002
- 2002
- English.
-
In: Diabetes Care. - : American Diabetes Association. - 0149-5992 .- 1935-5548. ; 25:5, s. 869-75
- Related links:
-
http://www.ncbi.nlm.... (free)
-
show more...
-
http://dx.doi.org/10... (free)
-
http://care.diabetes...
-
https://urn.kb.se/re...
-
https://lup.lub.lu.s...
-
https://doi.org/10.2...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVE: Glucagon-like peptide-1 (GLP-1) has been proposed as a new treatment modality for type 2 diabetes. To circumvent the drawback of the short half-life of GLP-1, inhibitors of the GLP-1-degrading enzyme dipeptidyl peptidase IV (DPP IV) have been examined. Such inhibitors improve glucose tolerance in insulin-resistant rats and mice. In this study, we examined the 4-week effect of 1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine (NVP DPP728), a selective, orally active inhibitor of DPP IV, in subjects with diet-controlled type 2 diabetes in a placebo-controlled double-blind multicenter study.RESEARCH DESIGN AND METHODS: A total of 93 patients (61 men and 32 women), aged 64 +/- 9 years (means +/- SD) and with BMI 27.3 +/- 2.7 kg/m(2), entered the study. Fasting blood glucose was 8.5 +/- 1.5 mmol/l, and HbA(1c) was 7.4 +/- 0.7%. Before and after treatment with NVP DPP728 at 100 mg x 3 (n = 31) or 150 mg x 5 (n = 32) or placebo (n = 30), subjects underwent a 24-h study with standardized meals (total 2,000 kcal).RESULTS: Compared with placebo, NVP DPP728 at 100 mg t.i.d. reduced fasting glucose by 1.0 mmol/l (mean), prandial glucose excursions by 1.2 mmol/l, and mean 24-h glucose levels by 1.0 mmol/l (all P < 0.001). Similar reductions were seen in the 150-mg b.i.d. treatment group. Mean 24-h insulin was reduced by 26 pmol/l in both groups (P = 0.017 and P = 0.023). Although not an efficacy parameter foreseen in the study protocol, HbA(1c) was reduced to 6.9 +/- 0.7% in the combined active treatment groups (P < 0.001). Laboratory safety and tolerability was good in all groups.CONCLUSIONS: We conclude that inhibition of DPP IV is a feasible approach to the treatment of type 2 diabetes in the early stage of the disease.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Ahrén, Bo
-
Simonsson, Erik
-
Larsson, Hillevi
-
Landin-Olsson, M ...
-
Torgeirsson, Hli ...
-
Jansson, Per-And ...
-
show more...
-
Sandqvist, Madel ...
-
Båvenholm, Peter
-
Efendic, Suad
-
Eriksson, Jan W
-
Dickinson, Sheil ...
-
Holmes, David
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Endocrinology an ...
- Articles in the publication
-
Diabetes Care
- By the university
-
Uppsala University
-
Lund University